Abstract:Disease modifying therapies aiming to preserve β-cell function in patients with adult-onset autoimmune type 1 diabetes are lacking. Here, we conducted a multi-centre, randomized, controlled trial to assess the β-cell preservation effects of saxagliptin alone and saxagliptin combined with vitamin D as adjunctive therapies in adult-onset autoimmune type 1 diabetes. In this 3-arm trial, 301 participants were randomly assigned to a 24-month course of the conventional therapy (metformin with or without insulin) or adjunctive saxagliptin or adjunctive saxagliptin plus vitamin D to the conventional therapy. The primary endpoint was the change from baseline to 24 months in the fasting C-peptide. The secondary endpoints included the area under the concentration-time curve (AUC) for C-peptide level in a 2-h mixed-meal tolerance test, glycemic control, total daily insulin use and safety, respectively. The primary endpoint was not achieved in saxagliptin plus vitamin D group (P = 0.18) and saxagliptin group (P = 0.26). However, compared with the conventional therapy, 2-h C-peptide AUC from 24 months to baseline decreased less with saxagliptin plus vitamin D (-276 pmol/L vs. -419 pmol/L; P = 0.01), and not to the same degree with saxagliptin alone (-314 pmol/L; P = 0.14). Notably, for participants with higher glutamic acid decarboxylase antibody (GADA) levels, the decline of β-cell function was much lower in saxagliptin plus vitamin D group than in the conventional therapy group (P = 0.001). Insulin dose was significantly reduced in both active treatment groups than in the conventional therapy group despite all groups having similar glycemic control. In conclusion, the combination of saxagliptin and vitamin D preserves pancreatic β-cell function in adult-onset autoimmune type 1 diabetes, an effect especially efficacious in individuals with higher GADA levels. Our results provide evidence for a novel adjunct to insulin and metformin as potential initial treatment for adult-onset type 1 diabetes. (ClinicalTrials.gov identifier: NCT02407899).

Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS)

Author Response for "saxagliptin Combined with Additional Oral Antihyperglycemic Agents in Drug‐naive Diabetic Patients with High Glycosylated Hemoglobin: a 24‐week, Multicenter, Randomized, Open‐label, Active Parallel‐controlled Group Clinical Trial in China (SUCCESS)"

Efficacy and Safety of Saxagliptin Compared with Acarbose in Chinese Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: Results of a Phase IV Open‐label Randomized Controlled Study (the SMART Study)

Saxagliptin Add-on Therapy in Chinese Patients with Type 2 Diabetes Inadequately Controlled by Insulin with or Without Metformin: Results from the SUPER Study, a Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.

Cost-Effectiveness Of Saxagliptin Versus Acarbose As Second-Line Therapy In Type 2 Diabetes In China

Comparative Effect Of Saxagliptin And Glimepiride With A Composite Endpoint Of Adequate Glycaemic Control Without Hypoglycaemia And Without Weight Gain In Patients Uncontrolled With Metformin Therapy: Results From The Specify Study, A 48-Week, Multi-Centre, Randomized, Controlled Trial

Cost-effectiveness of Saxagliptin Vs Glimepiride As a Second-Line Therapy Added to Metformin in Type 2 Diabetes in China

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Uptitration in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Randomized, Open-Label, Prospective Study (Vision)

The effectiveness and safety of saxagliptin combined with insulin glargine in the treatment of gerontal patients with type 2 diabetes mellitus

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.

Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension

Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial

Efficacy And Safety Of Saxagliptin In Patients With Type 2 Diabetes: A Systematic Review And Meta-Analysis

Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial

β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug naïve overweight or obese type 2 diabetes.

The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.